Waypoint €730 million acquisition of Stallergenes Greer

22/3/2019

Public acquisition

Value:

€ 730.1 million

Dollar value:

$ 822.263 million

Status:

Announced

Date:

22/3/2019

Overview:

Waypoint has reached an agreement to take over bio-pharmaceutical company Stallergenes Greer for €730 million.
Waypoint currently owns 84% of the target.
After the acquisition is completed Stallergenes Greer will be delisted from Euronext Paris.

Laura Mendes – Researcher

Jurisdictions:

France
United Kingdom

Deal type:

Public acquisition

Practice area:

M&A

Governing laws:

England and Wales
France

Industry sector:

Pharmaceuticals and life sciences

Firms:

Clifford Chance

Party: Stallergenes Greer (Seller)

Lawyers: Aline Cardin, Gilles Lebreton, Joel Ziff

Skadden Arps Slate Meagher & Flom

Party: Waypoint Group (Acquirer)

Lawyer: Pascal Bine

Related deals